Premium
An Activatable Theranostic for Targeted Cancer Therapy and Imaging
Author(s) -
Bhuniya Sankarprasad,
Maiti Sukhendu,
Kim EunJoong,
Lee Hyunseung,
Sessler Jonathan L.,
Hong Kwan Soo,
Kim Jong Seung
Publication year - 2014
Publication title -
angewandte chemie
Language(s) - English
Resource type - Journals
eISSN - 1521-3757
pISSN - 0044-8249
DOI - 10.1002/ange.201311133
Subject(s) - prodrug , hela , conjugate , in vivo , chemistry , biotinylation , fluorophore , ex vivo , in vitro , cancer research , biophysics , targeted therapy , drug delivery , biochemistry , cancer , fluorescence , medicine , biology , mathematical analysis , physics , mathematics , microbiology and biotechnology , organic chemistry , quantum mechanics
A new theranostic strategy is described. It is based on the use of an “all in one” prodrug, namely the biotinylated piperazine‐rhodol conjugate 4 a . This conjugate, which incorporates the anticancer drug SN‐38, undergoes self‐immolative cleavage when exposed to biological thiols. This leads to the tumor‐targeted release of the active SN‐38 payload along with fluorophore 1 a . This release is made selective as the result of the biotin functionality. Fluorophore 1 a is 32‐fold more fluorescent than prodrug 4 a . It permits the delivery and release of the SN‐38 payload to be monitored easily in vitro and in vivo, as inferred from cell studies and ex vivo analyses of mice xenografts derived from HeLa cells, respectively. Prodrug 4 a also displays anticancer activity in the HeLa cell murine xenograft tumor model. On the basis of these findings we suggest that the present strategy, which combines within a single agent the key functions of targeting, release, imaging, and treatment, may have a role to play in cancer diagnosis and therapy.